{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:12:48Z","timestamp":1793229168576,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.urolonc.2026.111076","type":"journal-article","created":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T12:12:43Z","timestamp":1774181563000},"page":"111076","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tumor size effect on cancer-specific mortality in T2N0M0 urothelial bladder cancer treated with trimodal therapy"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-0503","authenticated-orcid":false,"given":"Nick J.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Polverino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Quarta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Filzmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Petix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan A.","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Musi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix K.H.","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.urolonc.2026.111076_bib0001","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.6004\/jnccn.2017.0156","article-title":"Bladder cancer, version 5.2017, NCCN Clinical Practice Guidelines in oncology","volume":"15","author":"Spiess","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111076_bib0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JU.0000000000003981","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; Amended 2020, 2024)","volume":"212","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111076_bib0003","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 Guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111076_bib0004","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.juro.2008.11.023","article-title":"Effect of renal cancer size on the prevalence of metastasis at diagnosis and mortality","volume":"181","author":"Nguyen","year":"2009","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111076_bib0005","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0360-3016(03)00124-X","article-title":"Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer","volume":"56","author":"Chen","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111076_bib0006","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijrobp.2023.05.013","article-title":"Efficacy and safety of bladder preservation therapy in combination with Atezolizumab and radiation therapy (BPT-ART) for invasive bladder cancer: interim analysis from a multicenter, open-label, prospective phase 2 trial","volume":"117","author":"Kimura","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111076_bib0007","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.urolonc.2008.07.005","article-title":"Combined modality treatment with bladder preservation for muscle invasive bladder cancer","volume":"28","author":"Sabaa","year":"2010","journal-title":"Urol Oncol"},{"issue":"22","key":"10.1016\/j.urolonc.2026.111076_bib0008","doi-asserted-by":"crossref","first-page":"8491","DOI":"10.1002\/cam4.3478","article-title":"Trimodal therapy in T2-4aN0M0 bladder cancer\u2013how to select the best candidate?","volume":"9","author":"Gofrit","year":"2020","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111076_bib0009","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.eururo.2006.02.034","article-title":"Tumor size improves the accuracy of TNM predictions in patients with renal cancer","volume":"50","author":"Karakiewicz","year":"2006","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111076_bib0010","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.euf.2022.07.005","article-title":"Cancer-specific mortality in T1a renal cell carcinoma treated with local tumor destruction versus partial nephrectomy","volume":"9","author":"Sorce","year":"2023","journal-title":"Eur Urol Focus"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111076_bib0011","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2217\/cer-2020-0200","article-title":"A systematic review of noninferiority margins in oncology clinical trials","volume":"10","author":"Hashim","year":"2021","journal-title":"J Comp Eff Res"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111076_bib0012","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.euo.2024.01.014","article-title":"Benefit of neoadjuvant cisplatin-based chemotherapy for invasive bladder cancer patients treated with radiation-based therapy in a real-world setting: an inverse probability treatment weighted analysis","volume":"7","author":"Kool","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111076_bib0013","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.urolonc.2026.111076_bib0014","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","article-title":"Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic","volume":"35","author":"Kulkarni","year":"2017","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.urolonc.2026.111076_bib0015","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.3390\/cancers14235766","article-title":"Differences in cancer-specific mortality after trimodal therapy for T2N0M0 bladder cancer according to histological subtype","volume":"14","author":"Barletta","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T05:39:56Z","timestamp":1776577196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926000876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1078143926000876"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111076","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor size effect on cancer-specific mortality in T2N0M0 urothelial bladder cancer treated with trimodal therapy","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111076"}}